Covered recipient · General Payments record
STUART SHAFER
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$2,346.32
94 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,151.87 | 92 |
| Education | $194.45 | 2 |
By paying entity
PY2023 · entire year · sorted by reported total
Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
STUART SHAFER
NPI 1003818816 · CMS profile ID 171
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
VERO BEACH, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1003818816?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- STUART SHAFER, NPI 1003818816, CMS profile ID 171. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003818816?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). STUART SHAFER, NPI 1003818816, CMS profile ID 171. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003818816?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- STUART SHAFER, NPI 1003818816, CMS profile ID 171, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1003818816?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
94 matching records · $2,346.32 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–94 of 94.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| EMD Serono, Inc. | $35.80 | 05/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032343557 | CMS |
| Alnylam Pharmaceuticals Inc. | $27.52 | 05/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006153831 | CMS |
| Novartis Pharmaceuticals Corporation | $11.83 | 05/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 993257785 | CMS |
| Biogen, Inc. | $14.93 | 05/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1012202521 | CMS |
| AbbVie Inc. | $18.47 | 05/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998923599 | CMS |
| Celgene Corporation | $22.34 | 05/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015393859 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $33.64 | 05/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055594735 | CMS |
| Sumitomo Pharma America, Inc. | $26.36 | 05/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1030768083 | CMS |
| Genentech USA, Inc. | $114.57 | 05/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040567889 | CMS |
| Corium, LLC | $14.88 | 05/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 978417399 | CMS |
| InSightec,Inc | $14.58 | 05/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014517137 | CMS |
| Biogen, Inc. | $23.69 | 04/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1012196273 | CMS |
| AbbVie Inc. | $28.36 | 04/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998923593 | CMS |
| Novartis Pharmaceuticals Corporation | $2.40 | 04/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 993257775 | CMS |
| Novartis Pharmaceuticals Corporation | $11.78 | 04/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 993257777 | CMS |
| Lilly USA, LLC | $25.26 | 04/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032145291 | CMS |
| Alexion Pharmaceuticals, Inc. | $24.25 | 04/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016993715 | CMS |
| Amneal Pharmaceuticals LLC | $14.89 | 04/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053534509 | CMS |
| Horizon Therapeutics plc | $15.88 | 04/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 987072881 | CMS |
| Biogen, Inc. | $59.58 | 03/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1012127735 | CMS |
| Novartis Pharmaceuticals Corporation | $15.24 | 03/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 993257783 | CMS |
| Biogen, Inc. | $27.49 | 03/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1012257397 | CMS |
| SK Life Science, Inc. | $31.92 | 03/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1054807725 | CMS |
| Sumitomo Pharma America, Inc. | $15.96 | 03/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1030768085 | CMS |
| Otsuka America Pharmaceutical, Inc. | $22.00 | 03/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014802310 | CMS |
| Teva Pharmaceuticals USA, Inc. | $22.10 | 03/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056781645 | CMS |
| Genentech USA, Inc. | $13.90 | 03/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040567892 | CMS |
| EMD Serono, Inc. | $39.05 | 03/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032444009 | CMS |
| Biogen, Inc. | $22.91 | 02/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1012272539 | CMS |
| AbbVie Inc. | $5.86 | 02/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998923587 | CMS |
| Merz Pharmaceuticals, LLC | $26.09 | 02/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048303026 | CMS |
| EMD Serono, Inc. | $23.25 | 02/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032446689 | CMS |
| Amneal Pharmaceuticals LLC | $18.39 | 02/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053534503 | CMS |
| Celgene Corporation | $20.82 | 02/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015393779 | CMS |
| Alexion Pharmaceuticals, Inc. | $23.48 | 01/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017075295 | CMS |
| PFIZER INC. | $27.50 | 01/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049090907 | CMS |
| Biogen, Inc. | $25.00 | 01/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1012135763 | CMS |
| EMD Serono, Inc. | $24.82 | 01/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032432211 | CMS |
| ARGENX US, INC. | $15.07 | 01/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060432103 | CMS |
| Teva Pharmaceuticals USA, Inc. | $22.53 | 01/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056781625 | CMS |
| GENZYME CORPORATION | $94.99 | 01/05/2023 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049824423 | CMS |
| GENZYME CORPORATION | $33.71 | 01/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049824429 | CMS |
| Novartis Pharmaceuticals Corporation | $2.57 | 01/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 993257779 | CMS |
| Novartis Pharmaceuticals Corporation | $21.18 | 01/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 993257781 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $516,634.87 | 114 |
| PY2024 | Principal investigator | $581,844.54 | 71 |
| PY2023 | Principal investigator | $631,181.77 | 107 |
| PY2022 | Principal investigator | $645,256.25 | 113 |
| PY2021 | Principal investigator | $848,767.86 | 210 |
| PY2020 | Principal investigator | $889,316.35 | 161 |
| PY2019 | Principal investigator | $805,393.74 | 228 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
114 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Hoffmann-La Roche Limited | $144.00 | 12/01/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211609986 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $229.00 | 12/01/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211609991 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $85.00 | 12/01/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211609994 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $23,471.61 | 11/19/2025 | Non-covered Recipient Entity VERO BEACH NEUROLOGY | A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R | No dispute reported | 06/30/2026 | 1190306555 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,290.00 | 11/12/2025 | Non-covered Recipient Entity Geodyssey Research, Llc | A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) | No dispute reported | 06/30/2026 | 1235997161 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $143.00 | 11/12/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609666 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $78.00 | 11/12/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609676 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $123.11 | 11/05/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609670 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $68.00 | 11/05/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609680 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $3,799.00 | 10/28/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609971 |
| Principal investigator 1 | Roche Products Limited | $313.00 | 10/23/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609772 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,625.00 | 10/21/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609977 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $100.00 | 10/16/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609967 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $100.00 | 10/16/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609975 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $45.50 | 10/16/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609982 |
| Principal investigator 1 | Roche Products Limited | $237.40 | 10/16/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609777 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,107.73 | 10/08/2025 | Non-covered Recipient Entity MS CENTER OF VERO BEACH | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190302855 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $98.00 | 10/02/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609636 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $30.00 | 10/02/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609641 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $46.00 | 10/02/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609646 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $46.00 | 10/02/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609650 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $30.00 | 10/02/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609654 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $450.00 | 10/02/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609658 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $95.97 | 10/02/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609662 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $837.00 | 09/22/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609627 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $611.00 | 09/16/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609955 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,250.00 | 09/15/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609616 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $7,764.00 | 09/15/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609620 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $7,764.00 | 09/15/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609623 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,625.00 | 08/21/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609963 |
| Principal investigator 1 | Roche Products Limited | $313.00 | 08/21/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609733 |
| Principal investigator 1 | Roche Products Limited | $300.00 | 08/21/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609763 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $520.00 | 08/01/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609950 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $585.00 | 08/01/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609959 |
| Principal investigator 1 | Roche Products Limited | $313.00 | 07/24/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609726 |
| Principal investigator 1 | Roche Products Limited | $313.00 | 07/24/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609729 |
| Principal investigator 1 | Roche Products Limited | $313.00 | 07/24/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609737 |
| Principal investigator 1 | Roche Products Limited | $313.00 | 07/24/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609741 |
| Principal investigator 1 | Roche Products Limited | $313.00 | 07/24/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609744 |
| Principal investigator 1 | Roche Products Limited | $313.00 | 07/24/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609748 |
| Principal investigator 1 | Roche Products Limited | $313.00 | 07/24/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609756 |
| Principal investigator 1 | Roche Products Limited | $313.00 | 07/24/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609760 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $837.00 | 07/23/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609632 |
| Principal investigator 1 | Roche Products Limited | $600.00 | 07/03/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609753 |
| Principal investigator 1 | Roche Products Limited | $313.00 | 07/03/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609767 |
| Principal investigator 1 | Roche Products Limited | $313.00 | 06/19/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609687 |
| Principal investigator 1 | Roche Products Limited | $313.00 | 06/19/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609692 |
| Principal investigator 1 | Roche Products Limited | $313.00 | 06/19/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609698 |
| Principal investigator 1 | Roche Products Limited | $313.00 | 06/19/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609702 |
| Principal investigator 1 | Roche Products Limited | $313.00 | 06/19/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609717 |
| Principal investigator 1 | Roche Products Limited | $313.00 | 06/19/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609721 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $299.00 | 05/27/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609605 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $299.00 | 05/27/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609609 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $30.00 | 05/27/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609612 |
| Principal investigator 1 | Roche Products Limited | $313.00 | 05/22/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609713 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $397.00 | 05/20/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609923 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $22,142.00 | 05/13/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH, LLC | A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light | No dispute reported | 06/30/2026 | 1190299649 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,338.30 | 05/08/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609927 |
| Principal investigator 1 | Roche Products Limited | $313.00 | 05/08/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609707 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,625.00 | 05/01/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609932 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $7,659.90 | 04/24/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609919 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,792.00 | 04/24/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609936 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $74.62 | 04/17/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609941 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $780.00 | 04/17/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609945 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $500.00 | 03/12/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609568 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,250.00 | 03/12/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609571 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $84.99 | 03/12/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609584 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $68.00 | 03/12/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609588 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,250.00 | 03/12/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609592 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $30.00 | 03/12/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609596 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $26.00 | 03/06/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609793 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $324.00 | 03/06/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609823 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $40.50 | 03/06/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609865 |
| Principal investigator 1 | Celgene Corporation | $16,431.60 | 02/28/2025 | Non-covered Recipient Entity Geodyssey Research, Llc | A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) | No dispute reported | 06/30/2026 | 1222306931 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $736.00 | 02/25/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609892 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $384.00 | 02/20/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609797 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $508.00 | 02/20/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609809 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,191.00 | 02/20/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609817 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $604.00 | 02/20/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609846 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $456.00 | 02/20/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609869 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $294.00 | 02/20/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609888 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,288.00 | 02/19/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609576 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,288.00 | 02/19/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609580 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $144.00 | 02/13/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609800 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $736.00 | 02/13/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609831 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $3,799.00 | 02/13/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609854 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $45.50 | 02/11/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609835 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $585.00 | 02/11/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609884 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $585.00 | 02/11/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609896 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $100.00 | 02/06/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609781 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,625.00 | 02/06/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609850 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,625.00 | 02/06/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609881 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $85.00 | 02/06/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609915 |
| Principal investigator 1 | UCB SA | $4,300.00 | 02/06/2025 | Non-covered Recipient Entity Geodyssey Research, Llc | A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE | No dispute reported | 06/30/2026 | 1246657732 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $59.46 | 02/04/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609789 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $83.25 | 02/04/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609827 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $82.02 | 02/04/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609904 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $100.00 | 02/04/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609909 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $93,752.83 | 01/31/2025 | Non-covered Recipient Entity VERO BEACH NEUROLOGY | A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light | No dispute reported | 06/30/2026 | 1190306557 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $3,510.00 | 01/23/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609805 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $144.00 | 01/23/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609813 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,625.00 | 01/23/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609839 |
| Principal investigator 1 | Roche Products Limited | $313.00 | 01/23/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211609683 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $837.00 | 01/22/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211609600 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $59.55 | 01/21/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609786 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $100.00 | 01/21/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609843 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $100.00 | 01/21/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609873 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $100.00 | 01/21/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609877 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $98.00 | 01/21/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609900 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $100.00 | 01/21/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609913 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $36,826.08 | 01/16/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH, LLC | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190299645 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $98.00 | 01/14/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609857 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $100.00 | 01/09/2025 | Non-covered Recipient Entity GEODYSSEY RESEARCH LLC | Study of ocrelizumab in PPMS patients assessing upper limb function | No dispute reported | 06/30/2026 | 1211609861 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $232,643.95 | 01/09/2025 | Non-covered Recipient Entity MS CENTER OF VERO BEACH | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190302857 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2025 | Amount invested | $74,440.01 | 2 |
| PY2025 | Value of interest | $0.01 | 2 |
| PY2024 | Amount invested | $0.01 | 1 |
| PY2024 | Value of interest | $0.01 | 1 |
| PY2023 | Amount invested | $0.00 | 1 |
| PY2023 | Value of interest | $0.01 | 1 |
| PY2020 | Amount invested | $6,244.00 | 1 |
| PY2020 | Value of interest | $0.00 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
5 records · PY2020–2025
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2025 | SWAN VALLEY MEDICAL INCORPORATED | $0.01 | $0.01 | These shares were purchased or granted in past years. This is only to update the value of ownership, which is currently zero. The company is privately held with no public market for the sale of shares so as we stand at the end of 2025, the shares the doctors own are without value. | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1206074228 |
| PY2025 | SWAN VALLEY MEDICAL INCORPORATED | $74,440.00 | $0.00 | N/A | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1206088043 |
| PY2024 | SWAN VALLEY MEDICAL INCORPORATED | $0.01 | $0.01 | These shares were purchased or granted in past years. This is only to update the value of ownership, which is currently zero. The company is privately held with no public market for the sale of shares so as we stand at the end of 2024, the shares the doctors own are without value. | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1126843863 |
| PY2023 | SWAN VALLEY MEDICAL INCORPORATED | $0.00 | $0.01 | Shares listed were purchased or granted for services in past reported years. The current value of these shares is the par value of $0.01. The Company is a privately held C Corporation with no public market for the sale of its highly restricted stock. The Company is has never been profitable and its liabilities currently exceed its assets, with operating expenses exceeding its sales revenues. | Physician Covered Recipient | No dispute reported | 06/30/2026 | 984209047 |
| PY2020 | SWAN VALLEY MEDICAL INCORPORATED | $6,244.00 | $0.00 | N/A | Physician Covered Recipient | No dispute reported | 06/30/2026 | 739633983 |